T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: activation, suppression and exhaustion

References

• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Stenson M, Habermann TM, et al. Cd4 + T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001;19:720–726.
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39(1):61–73. Prepublished on 2013/07/31 as DOI 10.1016/j.immuni.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71:907–920.
   PubMed Web of Science ®Google Scholar
• Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 2014;63:247–257.
   PubMed Web of Science ®Google Scholar
• Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25:2546–2553.
   PubMed Web of Science ®Google Scholar
• Poschke I, Mougiakakos D, Hansson J, et al. Immature immunosuppressive CD14 + HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010;70:4335–4345.
   PubMed Web of Science ®Google Scholar
• Yuan XK, Zhao XK, Xia YC, et al. Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res 2011;39:1381–1391.
   PubMed Web of Science ®Google Scholar
• Huang A, Zhang B, Wang B, et al. Increased CD14(+)HLA-DR (+/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother 2013;62:1439–1451.
   PubMed Web of Science ®Google Scholar
• Arihara F, Mizukoshi E, Kitahara M, et al. Increase in CD14 + HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013;62:1421–1430.
   PubMed Web of Science ®Google Scholar
• Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008;135:234–243.
   PubMed Web of Science ®Google Scholar
• Lin Y, Gustafson MP, Bulur PA, et al. Immunosuppressive CD14 + HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood 2011;117:872–881.
   PubMed Web of Science ®Google Scholar
• Vuk-Pavlovic S, Bulur PA, Lin Y, et al. Immunosuppressive CD14 + HLA-DRlow/- monocytes in prostate cancer. Prostate 2010;70:443–455.
   PubMed Web of Science ®Google Scholar
• Gustafson MP, Lin Y, New KC, et al. Systemic immune suppression in glioblastoma: the interplay between CD14 + HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010;12:631–644.
   PubMed Web of Science ®Google Scholar
• Khalifa KA, Badawy HM, Radwan WM, et al. CD14 HLA-DR low/ monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma. Int J Lab Hematol 2014;36:650–655.
   PubMed Web of Science ®Google Scholar
• Miller TP, Lippman SM, Spier CM, et al. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 1988;82:370–372.
   PubMed Web of Science ®Google Scholar
• Rimsza LM, Roberts RA, Campo E, et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2006;107:1101–1107.
   PubMed Web of Science ®Google Scholar
• Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004;103:4251–4258.
   PubMed Web of Science ®Google Scholar
• Rimsza LM, Farinha P, Fuchs DA, et al. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma 2007;48:542–546.
   PubMed Web of Science ®Google Scholar
• Schwartz RH. T cell anergy. Annu Rev Immunol 2003;21:305–334.
   PubMed Web of Science ®Google Scholar
• Thurnher M, Radmayr C, Hobisch A, et al. Tumor-infiltrating T lymphocytes from renal-cell carcinoma express B7-1 (CD80): T-cell expansion by T-T cell co-stimulation. Int J Cancer 1995;62:559–564.
   PubMed Web of Science ®Google Scholar
• Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev 2009; 229:126–144.
   PubMed Web of Science ®Google Scholar
• Dorfman DM, Schultze JL, Shahsafaei A, et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997;90:4297–4306.
   PubMed Web of Science ®Google Scholar
• Chaperot L, Plumas J, Jacob MC, et al. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp Hematol 1999;27:479–488.
   PubMed Web of Science ®Google Scholar
• Liang S, Alard P, Zhao Y, et al. Conversion of CD4 + CD25- cells into CD4 + CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med 2005;201:127–137.
   PubMed Web of Science ®Google Scholar
• Tai X, Cowan M, Feigenbaum L, et al. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005;6:152–162.
   PubMed Web of Science ®Google Scholar
• Treiger BF, Leonard WJ, Svetlik P, et al. A secreted form of the human interleukin 2 receptor encoded by an “anchor minus” cDNA. J Immunol 1986;136:4099–4105.
   PubMed Web of Science ®Google Scholar
• Symons JA, Wood NC, Di Giovine FS, et al. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol 1988;141:2612–2618.
   PubMed Web of Science ®Google Scholar
• Maier LM, Anderson DE, Severson CA, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009;182:1541–1547.
   PubMed Web of Science ®Google Scholar
• Jones SA, Horiuchi S, Topley N, et al. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001;15:43–58.
   PubMed Web of Science ®Google Scholar
• Rubinstein MP, Kovar M, Purton JF, et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci USA 2006;103:9166–9171.
   PubMed Web of Science ®Google Scholar
• Stoklasek TA, Schluns KS, Lefrancois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006;177:6072–6080.
   PubMed Web of Science ®Google Scholar
• Fernandez-Botran R. Soluble cytokine receptors: basic immunology and clinical applications. Crit Rev Clin Lab Sci 1999; 36:165–224.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 2011;118:2809–2820.
   PubMed Web of Science ®Google Scholar
• Chung JS, Shiue LH, Duvic M, et al. Sezary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood 2011;117:3382–3390.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble and membrane-bound TGF-beta-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma. PLoS One 2013;8:e59456.
   PubMed Web of Science ®Google Scholar
• Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081–2095.
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683–765.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Regulatory role of T cells producing both interferon gamma and interleukin 10 in persistent infection. J Exp Med 2001;194:F53–F57.
   PubMed Web of Science ®Google Scholar
• Buer J, Lanoue A, Franzke A, et al. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo. J Exp Med 1998;187:177–183.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 2005;78:1043–1051.
   PubMed Web of Science ®Google Scholar
• Scott-Browne JP, Shafiani S, Tucker-Heard G, et al. Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis. J Exp Med 2007;204:2159–2169.
   PubMed Web of Science ®Google Scholar
• Sharma PK, Saha PK, Singh A, et al. FoxP3 + regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis. Am J Respir Crit Care Med 2009;179:1061–1070.
   PubMed Web of Science ®Google Scholar
• Gupta M, Han JJ, Stenson M, et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 2012;119:2844–2853.
   PubMed Web of Science ®Google Scholar
• Charbonneau B, Maurer MJ, Ansell SM, et al. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine 2012;60:882–889.
   PubMed Web of Science ®Google Scholar
• O’Garra A, Stapleton G, Dhar V, et al. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol 1990;2:821–832.
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915–924.
   PubMed Web of Science ®Google Scholar
• Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopula- tions with distinct T cell-suppressive activity. Blood 2008;111: 4233–4244.
   PubMed Web of Science ®Google Scholar
• Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008;181: 5791–5802.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12: 253–268.
   PubMed Web of Science ®Google Scholar
• Zea AH, Rodriguez PC, Atkins MB, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 2005;65:3044–3048.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69: 1553–1560.
   PubMed Web of Science ®Google Scholar
• Liu CY, Wang YM, Wang CL, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33 + myeloid-derived suppressor cells and CD8 + T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136:35–45.
   PubMed Web of Science ®Google Scholar
• Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011;60:1419–1430.
   PubMed Web of Science ®Google Scholar
• Mundy-Bosse BL, Young GS, Bauer T, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4(+) T cells from patients with GI malignancy. Cancer Immunol Immunother 2011;60:1269–1279.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162–174.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Fell R, Polliack A, et al. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol 2013;31:65–71.
   PubMed Web of Science ®Google Scholar
• Serafini P, Mgebroff S, Noonan K, et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 2008;68:5439–5449.
   PubMed Web of Science ®Google Scholar
• Schlecker E, Stojanovic A, Eisen C, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol 2012;189:5602–5611.
   PubMed Web of Science ®Google Scholar
• Gershon RK, Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology 1970;18: 723–737.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151–1164.
   PubMed Web of Science ®Google Scholar
• Suri-Payer E, Amar AZ, Thornton AM, et al. CD4 + CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998;160:1212–1218.
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766–4772.
   PubMed Web of Science ®Google Scholar
• Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003;9: 606–612.
   PubMed Web of Science ®Google Scholar
• Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756–2761.
   PubMed Web of Science ®Google Scholar
• Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4 + CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444–1453.
   PubMed Web of Science ®Google Scholar
• Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005;65:2457–2464.
   PubMed Web of Science ®Google Scholar
• Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272–4276.
   PubMed Web of Science ®Google Scholar
• Kono K, Kawaida H, Takahashi A, et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006;55:1064–1071.
   PubMed Web of Science ®Google Scholar
• Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25 + T cells. Immunology 2002;107:5–9.
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263–274.
   PubMed Web of Science ®Google Scholar
• Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-CD4 + CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13:2075–2081.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Stenson MJ, et al. Intratumoral CD4 + CD25+ regulatory T-cell-mediated suppression of infiltrating CD4 + T cells in B-cell non-Hodgkin lymphoma. Blood 2006;107:3639–3646.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Ziesmer SC, et al. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006;66:10145–10152.
   PubMed Web of Science ®Google Scholar
• Hilchey SP, De A, Rimsza LM, et al. Follicular lymphoma intratumoral CD4 + CD25+ GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8 + CD25- and CD4 + CD25- T cells. J Immunol 2007;178:4051–4061.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Ziesmer SC, et al. CD70 + non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4 + CD25 T cells. Blood 2007;110:2537–2544.
   PubMed Web of Science ®Google Scholar
• Mittal S, Marshall NA, Duncan L, et al. Local and systemic induction of CD4 + CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008;111:5359–5370.
   PubMed Web of Science ®Google Scholar
• Han Y, Wu J, Bi L, et al. Malignant B cells induce the conversion of CD4 + CD25- T cells to regulatory T cells in B-cell non-Hodgkin lymphoma. PLoS One 2011;6:e28649.
   PubMed Web of Science ®Google Scholar
• Ai WZ, Hou JZ, Zeiser R, et al. Follicular lymphoma B cells induce the conversion of conventional CD4 + T cells to T-regulatory cells. Int J Cancer 2009;124:239–244.
   PubMed Web of Science ®Google Scholar
• Gallimore A, Glithero A, Godkin A, et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med 1998;187:1383–1393.
   PubMed Web of Science ®Google Scholar
• Zajac AJ, Blattman JN, Murali-Krishna K, et al. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998;188:2205–2213.
   PubMed Web of Science ®Google Scholar
• Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350–354.
   PubMed Web of Science ®Google Scholar
• D’Souza M, Fontenot AP, Mack DG, et al. Programmed death 1 expression on HIV-specific CD4 + T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 2007;179: 1979–1987.
   PubMed Web of Science ®Google Scholar
• Ulsenheimer A, Gerlach JT, Gruener NH, et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 2003;37:1189–1198.
   PubMed Web of Science ®Google Scholar
• Urbani S, Amadei B, Tola D, et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006;80:11398–11403.
   PubMed Web of Science ®Google Scholar
• Kasprowicz V, Schulze Zur Wiesch J, Kuntzen T, et al. High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8 + and CD4 + T cells during acute HCV infection, irrespective of clinical outcome. J Virol 2008;82:3154–3160.
   PubMed Web of Science ®Google Scholar
• Klein L, Trautman L, Psarras S, et al. Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor. Eur J Immunol 2003;33:806–814.
   PubMed Web of Science ®Google Scholar
• Mumprecht S, Schurch C, Schwaller J, et al. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009;114:1528–1536.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114:1537–1544.
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients. J Exp Med 2010;207: 2175–2186.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207:2187–2194.
   PubMed Web of Science ®Google Scholar
• Gitelson E, Spaner D, Buckstein R, et al. T-cell analysis in identical twins reveals an impaired anti-follicular lymphoma immune response in the patient but not in the healthy twin. Br J Haematol 2002;116:122–127.
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Kobie JJ, Cochran MR, et al. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. J Immunol 2009;183: 6157–6166.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Grote DM, Ziesmer SC, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012;122: 1271–1282.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Grote DM, Xiu B, et al. TGF-beta upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia 2014;28:1872–1884.
   PubMed Web of Science ®Google Scholar